94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Kyeongseok Jeon1,2†Yuri Kim1†Shin Kwang Kang3†Uni Park1,2†Jayoun Kim4Nanhee Park4Jaemoon Koh5Man-Shik Shim3Minsoo Kim2Youn Ju Rhee3Hyeongseok Jeong6Siyoung Lee7Donghyun Park7Jinyoung Lim8Hyunsu Kim8Na-Young Ha9Hye-Yeong Jo10Sang Cheol Kim10Ju-Hee Lee10Jiwon Shon11Hoon Kim11,12Yoon Kyung Jeon5Youn-Soo Choi2Hye Young Kim2Won-Woo Lee1,2Murim Choi2Hyun-Young Park13Woong-Yang Park7,8*Yeon-Sook Kim6*
Nam-Hyuk Cho1,2,14,15,16*- 1Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
- 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
- 3Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine, Deajon, Republic of Korea
- 4Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea
- 5Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
- 6Department of Internal Medicine, Chungnam National University School of Medicine, Deajon, Republic of Korea
- 7Geninus Inc., Seoul, Republic of Korea
- 8Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea
- 9Chungnam National University Hospital, Biomedical Research Institute, Deajon, Republic of Korea
- 10Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
- 11Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea
- 12Biopharmaceutical Convergence Major, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea
- 13Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
- 14Institute of Endemic Diseases, Medical Research Center, Seoul National University, Seoul, Republic of Korea
- 15Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea
- 16Wide River Institute of Immunology, Seoul National University, Hongcheon, Gangwon-do, Republic of Korea
A Corrigendum on
Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia.
By Jeon K, Kim Y, Kang SK, Park U, Kim J, Park N, Koh J, Shim M-S, Kim M, Rhee YJ, Jeong H, Lee S, Park D, Lim J, Kim H, Ha N-Y, Jo H-Y, Kim SC, Lee J-H, Shon J, Kim H, Jeon YK, Choi Y-S, Kim HY, Lee W-W, Choi M, Park H-Y, Park W-Y, Kim Y-S and Cho N-H (2023) Front. Immunol. 14:1101808. doi: 10.3389/fimmu.2023.1101808
In the published article, there was a mistake in the Funding statement. The grant number for the National Research Foundation (NRF) funded by the Ministry of Science and ICT was displayed as “2021M3A9H5020761”. The correct Funding statement appears below.
This work was supported by grants from the Korea National Institute of Health Infrastructural Research Program (4800–4861–312–210–13), operation of data center for national biomedical data resources (2021-NI-017-00), the National Research Foundation (NRF) funded by the Ministry of Science and ICT (2021M3A9I2080490), 2022 Joint Research Project of Institutes of Science and Technology (to N-HC), and the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2022R1A6A3A1307317). KJ and UP received a scholarship from the BK21-plus education program provided by the National Research Foundation of Korea.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, SARS-CoV-2, pneumonia, inflammation, IFNa, IL-12p40
Citation: Jeon K, Kim Y, Kang SK, Park U, Kim J, Park N, Koh J, Shim M-S, Kim M, Rhee YJ, Jeong H, Lee S, Park D, Lim J, Kim H, Ha N-Y, Jo H-Y, Kim SC, Lee J-H, Shon J, Kim H, Jeon YK, Choi Y-S, Kim HY, Lee W-W, Choi M, Park H-Y, Park W-Y, Kim Y-S and Cho N-H (2023) Corrigendum: Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia. Front. Immunol. 14:1175767. doi: 10.3389/fimmu.2023.1175767
Received: 28 February 2023; Accepted: 02 March 2023;
Published: 08 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Jeon, Kim, Kang, Park, Kim, Park, Koh, Shim, Kim, Rhee, Jeong, Lee, Park, Lim, Kim, Ha, Jo, Kim, Lee, Shon, Kim, Jeon, Choi, Kim, Lee, Choi, Park, Park, Kim and Cho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Woong-Yang Park, d29vbmd5YW5nQGdtYWlsLmNvbQ==; Yeon-Sook Kim, aWRhbGljZWtpbUBnbWFpbC5jb20=; Nam-Hyuk Cho, Y2hvbmhAc251LmFjLmty
†These authors have contributed equally to this work and share first authorship